ACAD
Price
$22.20
Change
-$0.30 (-1.33%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
3.72B
33 days until earnings call
CRSP
Price
$46.74
Change
-$0.04 (-0.09%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
4.03B
45 days until earnings call
Interact to see
Advertisement

ACAD vs CRSP

Header iconACAD vs CRSP Comparison
Open Charts ACAD vs CRSPBanner chart's image
ACADIA Pharmaceuticals
Price$22.20
Change-$0.30 (-1.33%)
Volume$22.88K
Capitalization3.72B
CRISPR Therapeutics AG
Price$46.74
Change-$0.04 (-0.09%)
Volume$33.5K
Capitalization4.03B
ACAD vs CRSP Comparison Chart in %
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. CRSP commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Buy and CRSP is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (ACAD: $22.21 vs. CRSP: $46.70)
Brand notoriety: ACAD and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 80% vs. CRSP: 121%
Market capitalization -- ACAD: $3.72B vs. CRSP: $4.03B
ACAD [@Biotechnology] is valued at $3.72B. CRSP’s [@Biotechnology] market capitalization is $4.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while CRSP’s TA Score has 6 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 5 bearish.
  • CRSP’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -2.59% price change this week, while CRSP (@Biotechnology) price change was +5.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

CRSP is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.03B) has a higher market cap than ACAD($3.72B). ACAD YTD gains are higher at: 21.035 vs. CRSP (18.648). ACAD has higher annual earnings (EBITDA): 102M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. ACAD (682M). ACAD has less debt than CRSP: ACAD (56M) vs CRSP (219M). ACAD has higher revenues than CRSP: ACAD (996M) vs CRSP (35M).
ACADCRSPACAD / CRSP
Capitalization3.72B4.03B92%
EBITDA102M-455.24M-22%
Gain YTD21.03518.648113%
P/E Ratio16.21N/A-
Revenue996M35M2,846%
Total Cash682M1.86B37%
Total Debt56M219M26%
FUNDAMENTALS RATINGS
ACAD vs CRSP: Fundamental Ratings
ACAD
CRSP
OUTLOOK RATING
1..100
6424
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2694
PRICE GROWTH RATING
1..100
4142
P/E GROWTH RATING
1..100
9978
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (64) in the Biotechnology industry is in the same range as CRSP (67). This means that ACAD’s stock grew similarly to CRSP’s over the last 12 months.

ACAD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that ACAD’s stock grew similarly to CRSP’s over the last 12 months.

ACAD's SMR Rating (26) in the Biotechnology industry is significantly better than the same rating for CRSP (94). This means that ACAD’s stock grew significantly faster than CRSP’s over the last 12 months.

ACAD's Price Growth Rating (41) in the Biotechnology industry is in the same range as CRSP (42). This means that ACAD’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (78) in the Biotechnology industry is in the same range as ACAD (99). This means that CRSP’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADCRSP
RSI
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 9 days ago
73%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
72%
Bearish Trend 15 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SOVF29.930.45
+1.54%
Sovereign's Capital Flourish Fund
TEI5.920.08
+1.37%
Templeton Emerging Markets Income Fund
CWB82.080.58
+0.71%
SPDR® Blmbg Convert Secs ETF
HFRO5.230.01
+0.19%
Highland Opportunities and Income Fund
SHNY72.02-0.28
-0.39%
MicroSectors™ Gold 3X Leveraged ETN